Toward the design of mutation-resistant enzyme inhibitors: Further evaluation of the substrate envelope hypothesis

Chemical Biology and Drug Design

Volumn 74, Issue 3, 2009, Pages 234-245

  Kairys, Visvaldas ^a   Gilson, Michael K ^b   Lather, Viney ^a   Schiffer, Celia A ^c   Fernandes, Miguel X ^a  

^a Centro de Quimica da Madeira   (Portugal)

^b UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Mutation resistance; Substrate envelope

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ABELSON KINASE; AMPRENAVIR; ARGADIN; ARGIFIN; BW 1843 U 89; CHITINASE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DESCHLOROPYRIMETHAMINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; GLYCOSIDASE INHIBITOR; IMATINIB; NELFINAVIR; OSELTAMIVIR; PENTOXIFYLLINE; PERAMIVIR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; PYRIMETHAMINE; RALTITREXED; RITONAVIR; SAQUINAVIR; SIALIDASE; SIALIDASE INHIBITOR; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG TARGETING; ENZYME CONFORMATION; ENZYME SUBSTRATE; MUTATION; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

CHITINASE; COMPUTER SIMULATION; DRUG DESIGN; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HIV PROTEASE; HUMANS; MUTATION; NEURAMINIDASE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-ABL; SOFTWARE; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 68949201698     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00851.x     Document Type: Article

References (42)

1. Soulsby E.J. (2005) Resistance to antimicrobials in humans and animals. Br Med J 331 : 1219 1220.
2. Dorman S.E., Chaisson R.E. (2007) From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 13 : 295 298.
3. Hochhaus A., Erben P., Ernst T., Mueller M.C. (2007) Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 44 : S15 S24.
4. Longley D.B., Johnston P.G. (2005) Molecular mechanisms of drug resistance. J Pathol 205 : 275 292.
5. Ohtaka H., Freire E. (2005) Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol 88 : 193 208.
6. King N.M., Prabu-Jeyabalan M., Nalivaika E.A., Schiffer C.A. (2004) Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol 11 : 1333 1338.
7. Hellen C.U.T., Kräusslich H.-G., Wimmer E. (1989) Proteolytic processing of polyproteins in the replication of RNA viruses. Biochemistry 28 : 9881 9890.
8. Chellappan S., Kairys V., Fernandes M.X., Schiffer C., Gilson M.K. (2007) Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins 68 : 561 567.
9. Chellappan S., Reddy G.S.K.K., Ali A., Nalam M.N.L., Anjum S.G., Cao H., Kairys V., Fernandes M.X., Altman M.D., Tidor B., Rana T.M., Schiffer C.A., Gilson M.K. (2007) Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des 69 : 298 313.
10. Altman M.D., Ali A., Reddy G.S., Nalam M.N., Anjum S.G., Cao H., Chellappan S., Kairys V., Fernandes M.X., Gilson M.K., Schiffer C.A., Rana T.M., Tidor B. (2008) HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc 130 : 6099 6113.
11. Schiffer C.A. (2008) Combating drug resistance - identifying resilient molecular targets and robust drugs. In : Stroud R.M., Finer-Moore J., editors. Computational and structural approaches to drug discovery. The Royal Society of Chemistry, Cambridge, UK p. 127 133.
12. Varghese J.N., Smith P.W., Sollis S.L., Blick T.J., Sahasrabudhe A., McKimm-Breschkin J.L., Colman P.M. (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6 : 735 746.
13. Colman P.M. (2002) Neuraminidase inhibitors as antivirals. Vaccine 20 (Suppl 2 S55 S58.
14. Colman P.M. (2005) Zanamivir: an influenza virus neuraminidase inhibitor. Expert Rev Anti Infect Ther 3 : 191 199.
15. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H. et al. (2000) The Protein Data Bank. Nucl Acids Res 28 : 235 242.
16. Liu T., Lin Y., Wen X., Jorissen R.N., Gilson M.K. (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35 : D198 D201.
17. Bondi A. (1964) van der Waals volumes and radii. J Phys Chem 68 : 441 451.
18. Jung J., Lee B. (2000) Protein structure alignment using environmental profiles. Protein Eng 13 : 535 543.
19. Ren R. (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5 : 172 183.
20. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., Sawyers C.L. (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117 : 2562 2569.
21. Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M., Cole P.A., Kuriyan J. (2006) A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 4 : e144.
22. Hurtado-Guerrero R., van Aalten D.M.F. (2007) Structure of Saccharomyces cerevisiae chitinase 1 and screening-based discovery of potent inhibitors. Chem Biol 14 : 589 599.
23. Rao F.V., Houston D.R., Boot R.G., Aerts J.M.F.G., Hodkinson M., Adams D.J., Shiomi K., Ōmura S., van Aalten D.M.F (2005) Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases. Chem Biol 12 : 65 76.
24. van Aalten D.M.F., Komander D., Synstad B., Gåseidnes S, Peter M.G., Eijsink V.G.H. (2001) Structural insights into the catalytic mechanism of a family 18 exo-chitinase. Proc Natl Acad Sci USA 98 : 8979 8984.
25. MacKerell A.D. Jr., Bashford D., Bellott M., Dunbrack R.L., Evanseck J.D., Field M.J., Fischer S. et al. (1998) All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. J Phys Chem B 102 : 3586 3616.
26. Mayo S.L., Olafson B.D., Goddard W.A. (1990) DREIDING: a generic force field for molecular simulations. J Phys Chem 94 : 8897 8909.
27. Houston D.R., Shiomi K., Arai N., Ōmura S., Peter M.G., Turberg A., Synstad B., Eijsink V.G.H., van Aalten D.M.F. (2002) High-resolution structures of a chitinase complexed with natural product cyclopentapeptide inhibitors: mimicry of carbohydrate substrate. Proc Natl Acad Sci U S A 99 : 9127 9132.
28. Costi M.P., Ferrari S., Venturelli A., Calò S., Tondi D., Barlocco D. (2005) Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem 12 : 2241 2258.
29. McGuire J.J. (2003) Anticancer antifolates: current status and future directions. Curr Pharm Des 9 : 2593 2613.
30. Hawser S., Lociuro S., Islam K. (2006) Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71 : 941 948.
31. Anderson A.C. (2005) Targeting DHFR in parasitic protozoa. Drug Discov Today 10 : 121 128.
32. Moscona A. (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353 : 1363 1373.
33. Reece P.A. (2007) Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 79 : 1577 1586.
34. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V. et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102 : 11011 11016.
35. Rao F.V., Andersen O.A., Vora K.A., DeMartino J.A., van Aalten D.M.F. (2005) Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes. Chem Biol 12 : 973 980.
36. Tong Y., Liu-Chen X., Ercikan-Abali E.A., Capiaux G.M., Zhao S.C., Banerjee D., Bertino J.R. (1998) Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J Biol Chem 273 : 11611 11618.
37. Tong Y., Liu-Chen X., Ercikan-Abali E.A., Zhao S.C., Banerjee D., Maley F., Bertino J.R. (1998) Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. Generation of mutants that confer resistance to raltitrexed, Thymitaq, and BW1843U89. J Biol Chem 273 : 31209 31214.
38. Yuvaniyama J., Chitnumsub P., Kamchonwongpaisan S., Vanichtanankul J., Sirawaraporn W., Taylor P., Walkinshaw M.D., Yuthavong Y. (2003) Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 10 : 357 365.
39. Kongsaeree P., Khongsuk P., Leartsakulpanich U., Chitnumsub P., Tarnchompoo B., Walkinshaw M.D., Yuthavong Y. (2005) Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci U S A 102 : 13046 13051.
40. Smith B.J., McKimm-Breshkin J.L., McDonald M., Fernley R.T., Varghese J.N., Colman P.M. (2002) Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 45 : 2207 2212.
41. Gubareva L.V., Webster R.G., Hayden F.G. (2001) Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45 : 3403 3408.
42. Humphrey W., Dalke A., Schulten K. (1996) VMD: visual molecular dynamics. J Mol Graph 14 : 33 38.